MR spectroscopy in multiple sclerosis

Journal of Neuroimaging

Volumn 17, Issue SUPPL. 1, 2007, Pages

  De Stefano, Nicola ^a   Filippi, Massimo ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Magnetic resonance; Magnetic resonance spectroscopy; Multiple sclerosis

Indexed keywords

ARTICLE; BRAIN TISSUE; CLINICAL STUDY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE;

ASPARTIC ACID; BRAIN CHEMISTRY; CHOLINE; CREATINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS;

EID: 34147189667     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2007.00134.x     Document Type: Article

References (57)

1. Lin A, Ross BD, Harris K, et al. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2005;2:197-214.
2. De Stefano N, Bartolozzi ML, Guidi L, et al. Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis. J Neurol Sci 2005;233:203-208.
3. Matthews PM, De Stefano N, Narayanan S, et al. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 1998;18:327-336.
4. Trapp BD, Ransohoff RM, Fisher E, et al. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999;5:48-57.
5. Tartaglia MC, Narayanan S, De Stefano N, et al. Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol 2002;249:1382-1390.
6. Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125:2342-2352.
7. Gordon RE, Hanley PE, Shaw D, et al. Localization of metabolites in animals using 31P topical magnetic resonance. Nature 1980;287:736-738.
8. Gonen O, Viswanathan AK, Catalaa I, et al. Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med 1998;40:684-689.
9. Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec 2001;265:54-84.
10. Provencher SW.Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR in Biomed 2001;14:260-264.
11. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58.
12. De Stefano N, Matthews PM, Antel JP et al. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38:901-909.
13. Narayana PA,Doyle TJ, Lai D, et al. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Anna Neurol 1998;43:56-71.
14. Coyle JT, Robinson MB, Blakely RD, et al. The neurobiology of N-acetyl-aspartyl-glutamate. In: Barnard EA, Costa E, eds. Allosteric modulation of amino acid receptors: therapeutic implications. Raven Press, New York, 1989, 319-333.
15. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991;45:37-45.
16. Moffett JR, Namboodiri MAA, Cangro CB, et al. Immunohistochemical localization of N-acetylaspartate in rat brain. NeuroReport 1991;2:131-134.
17. Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005;128:1016-1025.
18. Bitsch A, Bruhn H, Vougioukas V, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR 1999;20:1619-1627.
19. Kapeller P, Brex PA, Chard D, et al. Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2002;8:207-210.
20. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995;34:721-727.
21. Arnold DL, Matthews PM, Francis G, et al. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990;14:154-159.
22. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990;40:1764-1769.
23. Husted CA, Goodin DS, Hugg JW, et al. Biochemical alterations in multiple sclerosis lesions and normal- appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 1994;36:157-165.
24. Narayanan S, Fu L, Pioro E, De Stefano N, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41:385-391.
25. Davie CA, Barker GJ, Thompson AJ, et al. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;63:736-742.
26. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998;121:103-113.
27. Sarchielli P, Presciutti O, Pelliccioli GP, et al. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 1999;122:513-521.
28. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70.
29. Falini A, Calabrese G, Filippi M, et al. Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. AJNR Am J Neuroradiol 1998;19:223-229.
30. De Stefano N, Narayanan S, Matthews PM, et al. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999;122:1933-1939.
31. Arnold DL. Changes observed in multiple sclerosis using magnetic resonance imaging reflect a focal pathology distributed along axonal pathways. J Neurol 2005;252(suppl 5):v25-v29.
32. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. New Engl J Med 1998;338:278-285.
33. De Stefano N, Narayanan S, Francis SJ, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 2002;59:1565-1571.
34. Fernando KT, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2004;127:1361-1369.
35. Schubert F, Seifert F, Elster C, et al. Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-beta therapy on absolute metabolite concentrations. MAGMA 2002;14:213-222.
36. Vrenken H, Barkhof F, Uitdehaag BM, et al. MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med 2005;53:256-266.
37. Filippi M, Rocca MA, Martino G, et al. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998;43:809-814.
38. Pike GB, De Stefano N, Narayanan S, et al. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology 2000;215:824-830.
39. Filippi M. Multiple sclerosis: a white matter disease with associated gray matter damage. J Neurol Sci 2001;185:3-4.
40. Sharma R, Narayana PA,Wolinsky JS. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult Scler 2001;7:221-226.
41. Sarchielli P, Presciutti O, Tarducci R, et al. Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis. J Neurol 2002;249:902-910.
42. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433-437.
43. Adalsteinsson E, Langer-Gould A, Homer RJ, et al. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2003;24:1941-1945.
44. Sastre-Garriga J, Ingle GT, Chard DT, et al. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol 2005;62:569-573.
45. Wylezinska M, Cifelli A, Jezzard P, et al. Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology 2003;60:1949-1954.
46. Inglese M, Liu S, Babb JS, et al. Three-dimensional proton spectroscopy of deep gray matter nuclei in relapsingremitting MS. Neurology 2004;63:170-172.
47. Geurts JJ, Reuling IE, Vrenken H, et al. MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magn Reson Med 2006;55:478-483.
48. Cifelli A, Arridge M, Jezzard P, et al. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650-653.
49. Urenjak J, Williams SR, Gadian DG, et al. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13:981-989.
50. Caramanos Z, Narayanan S, Arnold DL. 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain 2005;128:2483-2506.
51. Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;118:1583-1592.
52. De Stefano N, Matthews PM, Narayanan S, et al. Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient. Neurology 1997;49:1138-1141.
53. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121:1469-1477.
54. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001;50:169-180.
55. Gonen O, Grossman RI. The accuracy of whole brain N-acetylaspartate quantification. Magn Reson Imaging 2000;18:1255-1258.
56. Li BS, Babb JS, Soher BJ,. Reproducibility of 3D proton spectroscopy in the human brain. Magn Reson Med 2002;47:439-446.
57. Li BS, Wang H, Gonen O. Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magn Reson Imaging 2003;21:923-928.